Precipio, Inc. (PRPO)
USD 5.56
(-3.81%)
USD 5.56
(-3.81%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 13.63 Million USD | -20.81% |
| 2022 | 15.3 Million USD | 27.51% |
| 2021 | 12 Million USD | 16.6% |
| 2020 | 10.29 Million USD | 6.99% |
| 2019 | 9.62 Million USD | 1.81% |
| 2018 | 9.45 Million USD | 45.68% |
| 2017 | 6.48 Million USD | -14.79% |
| 2016 | 7.61 Million USD | -14.53% |
| 2015 | 8.9 Million USD | -67.06% |
| 2014 | 27.04 Million USD | -4.29% |
| 2013 | 28.25 Million USD | 15.26% |
| 2012 | 24.51 Million USD | 14.72% |
| 2011 | 21.36 Million USD | 61.41% |
| 2010 | 13.23 Million USD | -1.95% |
| 2009 | 13.5 Million USD | 1.82% |
| 2008 | 13.26 Million USD | -8.55% |
| 2007 | 14.49 Million USD | -0.01% |
| 2006 | 14.5 Million USD | -2.3% |
| 2005 | 14.84 Million USD | -57.21% |
| 2004 | 34.68 Million USD | 10.45% |
| 2003 | 31.4 Million USD | -13.73% |
| 2002 | 36.4 Million USD | 17.39% |
| 2001 | 31 Million USD | 26.73% |
| 2000 | 24.46 Million USD | 26.5% |
| 1999 | 19.34 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 2.62 Million USD | -12.22% |
| 2024 Q1 | 2.99 Million USD | 19.9% |
| 2023 Q1 | 3.77 Million USD | 29.1% |
| 2023 FY | 12.12 Million USD | -20.81% |
| 2023 Q4 | 2.49 Million USD | -25.08% |
| 2023 Q3 | 3.33 Million USD | -9.01% |
| 2023 Q2 | 3.66 Million USD | -2.97% |
| 2022 Q2 | 3.2 Million USD | -41.84% |
| 2022 FY | 15.3 Million USD | 27.51% |
| 2022 Q3 | 3.66 Million USD | 14.32% |
| 2022 Q4 | 2.92 Million USD | -20.22% |
| 2022 Q1 | 5.51 Million USD | 55.27% |
| 2021 FY | 12 Million USD | 16.6% |
| 2021 Q2 | 2.88 Million USD | 10.67% |
| 2021 Q3 | 2.96 Million USD | 2.91% |
| 2021 Q4 | 3.55 Million USD | 19.65% |
| 2021 Q1 | 2.6 Million USD | -4.54% |
| 2020 Q2 | 2.43 Million USD | 4.38% |
| 2020 FY | 10.29 Million USD | 6.99% |
| 2020 Q3 | 2.8 Million USD | 15.6% |
| 2020 Q4 | 2.72 Million USD | -2.85% |
| 2020 Q1 | 2.32 Million USD | -12.74% |
| 2019 FY | 9.62 Million USD | 1.81% |
| 2019 Q1 | 2.09 Million USD | 0.58% |
| 2019 Q2 | 2.46 Million USD | 17.64% |
| 2019 Q3 | 2.39 Million USD | -3.08% |
| 2019 Q4 | 2.66 Million USD | 11.59% |
| 2018 Q1 | 2.17 Million USD | -13.12% |
| 2018 FY | 9.45 Million USD | 45.68% |
| 2018 Q4 | 2.08 Million USD | -26.35% |
| 2018 Q3 | 2.83 Million USD | 20.06% |
| 2018 Q2 | 2.35 Million USD | 8.26% |
| 2017 FY | 6.48 Million USD | -14.79% |
| 2017 Q1 | 1.75 Million USD | -18.68% |
| 2017 Q2 | 777 Thousand USD | -55.7% |
| 2017 Q4 | 2.5 Million USD | -1.34% |
| 2017 Q3 | 2.54 Million USD | 227.03% |
| 2016 Q2 | 1.83 Million USD | -6.89% |
| 2016 Q4 | 2.15 Million USD | 31.12% |
| 2016 FY | 7.61 Million USD | -14.53% |
| 2016 Q1 | 1.97 Million USD | 138.97% |
| 2016 Q3 | 1.64 Million USD | -10.5% |
| 2015 Q3 | 3.66 Million USD | -35.14% |
| 2015 FY | 8.9 Million USD | -67.06% |
| 2015 Q2 | 5.64 Million USD | 0.5% |
| 2015 Q1 | 5.62 Million USD | -33.4% |
| 2015 Q4 | -5.06 Million USD | -238.26% |
| 2014 Q2 | 6.34 Million USD | 5.22% |
| 2014 FY | 27.04 Million USD | -4.29% |
| 2014 Q1 | 6.03 Million USD | -2.14% |
| 2014 Q4 | 8.44 Million USD | 35.65% |
| 2014 Q3 | 6.22 Million USD | -1.98% |
| 2013 FY | 28.25 Million USD | 15.26% |
| 2013 Q4 | 6.16 Million USD | -25.34% |
| 2013 Q2 | 6.33 Million USD | -15.58% |
| 2013 Q3 | 8.25 Million USD | 30.4% |
| 2013 Q1 | 7.5 Million USD | 10.11% |
| 2012 Q3 | 6.22 Million USD | 4.97% |
| 2012 Q4 | 6.81 Million USD | 9.39% |
| 2012 Q2 | 5.93 Million USD | 7.02% |
| 2012 Q1 | 5.54 Million USD | 1.78% |
| 2012 FY | 24.51 Million USD | 14.72% |
| 2011 Q4 | 5.44 Million USD | 11.62% |
| 2011 Q3 | 4.87 Million USD | -20.9% |
| 2011 Q2 | 6.16 Million USD | 26.39% |
| 2011 Q1 | 4.88 Million USD | 33.22% |
| 2011 FY | 21.36 Million USD | 61.41% |
| 2010 Q3 | 2.77 Million USD | -21.81% |
| 2010 Q4 | 3.66 Million USD | 32.14% |
| 2010 Q2 | 3.54 Million USD | 8.78% |
| 2010 FY | 13.23 Million USD | -1.95% |
| 2010 Q1 | 3.25 Million USD | 4.76% |
| 2009 FY | 13.5 Million USD | 1.82% |
| 2009 Q1 | 3.81 Million USD | 45.76% |
| 2009 Q4 | 3.11 Million USD | -1.33% |
| 2009 Q3 | 3.15 Million USD | -7.75% |
| 2009 Q2 | 3.41 Million USD | -10.5% |
| 2008 Q2 | 3.65 Million USD | 2.93% |
| 2008 Q1 | 3.54 Million USD | 1.05% |
| 2008 Q3 | 3.44 Million USD | -5.75% |
| 2008 Q4 | 2.62 Million USD | -23.86% |
| 2008 FY | 13.26 Million USD | -8.55% |
| 2007 Q3 | 3.39 Million USD | -4.69% |
| 2007 Q1 | 4.03 Million USD | 2.36% |
| 2007 FY | 14.49 Million USD | -0.01% |
| 2007 Q4 | 3.51 Million USD | 3.48% |
| 2007 Q2 | 3.55 Million USD | -11.86% |
| 2006 Q4 | 3.94 Million USD | 1.39% |
| 2006 Q2 | 3.35 Million USD | 1.15% |
| 2006 Q3 | 3.89 Million USD | 16.11% |
| 2006 Q1 | 3.31 Million USD | 15.19% |
| 2006 FY | 14.5 Million USD | -2.3% |
| 2005 FY | 14.84 Million USD | -57.21% |
| 2005 Q2 | 4.11 Million USD | -1.91% |
| 2005 Q3 | 3.64 Million USD | -11.56% |
| 2005 Q4 | 2.87 Million USD | -21.03% |
| 2005 Q1 | 4.19 Million USD | -6.9% |
| 2004 Q2 | 17.9 Million USD | 189.99% |
| 2004 Q3 | 6.09 Million USD | -65.95% |
| 2004 Q4 | 4.5 Million USD | -26.03% |
| 2004 FY | 34.68 Million USD | 10.45% |
| 2004 Q1 | 6.17 Million USD | -44.2% |
| 2003 Q2 | 6.62 Million USD | -4.89% |
| 2003 Q3 | 6.74 Million USD | 1.74% |
| 2003 Q4 | 11.06 Million USD | 64.11% |
| 2003 Q1 | 6.96 Million USD | -28.14% |
| 2003 FY | 31.4 Million USD | -13.73% |
| 2002 Q2 | 8.92 Million USD | 2.75% |
| 2002 Q4 | 9.69 Million USD | 6.81% |
| 2002 Q1 | 8.68 Million USD | -3.68% |
| 2002 FY | 36.4 Million USD | 17.39% |
| 2002 Q3 | 9.07 Million USD | 1.76% |
| 2001 Q4 | 9.01 Million USD | 11.52% |
| 2001 FY | 31 Million USD | 26.73% |
| 2001 Q1 | 6.27 Million USD | 0.03% |
| 2001 Q2 | 7.63 Million USD | 21.64% |
| 2001 Q3 | 8.08 Million USD | 5.89% |
| 2000 FY | 24.46 Million USD | 26.5% |
| 2000 Q1 | 6.64 Million USD | 0.0% |
| 2000 Q2 | 5.63 Million USD | -15.15% |
| 2000 Q3 | 5.85 Million USD | 3.81% |
| 2000 Q4 | 6.27 Million USD | 7.24% |
| 1999 FY | 19.34 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bionano Genomics, Inc. | 148.99 Million USD | 90.847% |
| Prenetics Global Limited | 60.73 Million USD | 77.546% |
| Star Equity Holdings, Inc. | 16.27 Million USD | 16.187% |
| CareDx, Inc | 277.76 Million USD | 95.09% |
| Exact Sciences Corporation | 2.06 Billion USD | 99.338% |
| Exagen Inc. | 52.29 Million USD | 73.92% |
| Inotiv, Inc. | 246.9 Million USD | 94.476% |
| Guardant Health, Inc. | 901.62 Million USD | 98.487% |
| Biodesix, Inc. | 77.41 Million USD | 82.384% |
| BioNexus Gene Lab Corp. | 3.92 Million USD | -247.634% |
| iSpecimen Inc. | 16.27 Million USD | 16.214% |
| Natera, Inc. | 938.98 Million USD | 98.548% |
| Aspira Women's Health Inc. | 24.11 Million USD | 43.444% |
| Standard BioTools Inc. | 113.48 Million USD | 87.983% |
| 23andMe Holding Co. | 420.73 Million USD | 96.759% |
| Castle Biosciences, Inc. | 242.78 Million USD | 94.383% |
| Personalis, Inc. | 128.14 Million USD | 89.357% |
| Aclaris Therapeutics, Inc. | 110.52 Million USD | 87.661% |
| Applied DNA Sciences, Inc. | 16.48 Million USD | 17.279% |
| OpGen, Inc. | 30.65 Million USD | 55.516% |
| T2 Biosystems, Inc. | 41.49 Million USD | 67.133% |
| Myriad Genetics, Inc. | 600.1 Million USD | 97.727% |
| ICON Public Limited Company | 755.64 Million USD | 98.195% |
| NeoGenomics, Inc. | 341.25 Million USD | 96.004% |
| Star Equity Holdings, Inc. | 16.27 Million USD | 16.187% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 98.752% |
| RadNet, Inc. | 268.87 Million USD | 94.928% |
| MDxHealth SA | 71.25 Million USD | 80.861% |
| Psychemedics Corporation | 11.33 Million USD | -20.328% |
| Illumina, Inc. | 3.81 Billion USD | 99.642% |
| Check-Cap Ltd. | 19.28 Million USD | 29.289% |
| Twist Bioscience Corporation | 354.18 Million USD | 96.149% |
| DarioHealth Corp. | 62.17 Million USD | 78.064% |
| Fulgent Genetics, Inc. | 171.9 Million USD | 92.067% |
| Sera Prognostics, Inc. | 39.91 Million USD | 65.834% |
| ENDRA Life Sciences Inc. | 10.52 Million USD | -29.63% |
| OPKO Health, Inc. | 574.68 Million USD | 97.627% |
| Medpace Holdings, Inc. | 187.68 Million USD | 92.733% |
| Neogen Corporation | 405.23 Million USD | 96.635% |
| Intelligent Bio Solutions Inc. | 11.7 Million USD | -16.476% |
| Prenetics Global Limited | 60.73 Million USD | 77.546% |
| Mainz Biomed B.V. | 27.15 Million USD | 49.776% |
| bioAffinity Technologies, Inc. | 8.76 Million USD | -55.599% |
| Trinity Biotech plc | 46.49 Million USD | 70.668% |
| Neuronetics, Inc. | 82.25 Million USD | 83.421% |
| Sotera Health Company | 300.46 Million USD | 95.461% |
| bioAffinity Technologies, Inc. | 8.76 Million USD | -55.599% |